CardioExchange Archive

February 23rd, 2015

Selections from Richard Lehman’s Literature Review: February 23rd

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of fondaparinux and low-molecular-weight heparin in patients with non-STEMI and a study of multiple BP medications, achieved BP, and mortality in older nursing home residents.

---

May 13th, 2011

Simultaneous TIA and ACS After Aspirin Cessation for Palpebral Surgery

Jean-Pierre Usdin, MD and James Fang, MD

A 77-year-old man with metformin-treated type 2 diabetes, high blood pressure, moderate renal insufficiency, stable angina, and a history of phlebitis stopped taking aspirin in preparation for palpebral surgery. A day after the surgery, he presented to the ER with two transient ischemic attacks (TIAs) affecting the left arm. The patient complained to the examining neurologist of […]

---

October 22nd, 2010

Warfarin or Dabigatran? The Thick and Thin of Deciding on an Anticoagulant

Anju Nohria, MD

These four patients are receiving chronic anticoagulation therapy. Read the descriptions of their cases and decide which, if any, of them you would switch to dabigatran.   Case 1  A 69-year-old man with a history of hypertension and colon cancer was found to be in atrial fibrillation during a preoperative assessment for colon resection. Metoprolol was […]

---

September 23rd, 2010

Fondaparinux Effective in Superficial-Vein Thrombosis

Larry Husten, PHD

In the randomized, double-blind CALISTO (Comparison of Arixtra in Lower Limb Superficial Vein Thrombosis with Placebo) trial, 3002 patients with acute, symptomatic superficial-vein thrombosis in the legs, but without DVT or symptomatic PE, received either fondaparinux (2.5 mg) or placebo for 45 days. The primary efficacy endpoint ─ a composite of all-cause death, symptomatic PE […]

---

August 31st, 2010

No Benefits for Low-Dose Heparin Over Standard Heparin in FUTURA/OASIS-8

Larry Husten, PHD

FUTURA (Fondaparinux Trial With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes)/OASIS-8 is the first trial to compare low-dose unfractionated heparin with conventional heparin dosing in PCI patients receiving fondaparinux. Sanjit Jolly and colleagues randomized 2026 non-STEMI high-risk patients undergoing PCI within 72 hours to either low-dose unfractionated heparin or a standard dose of heparin […]

---